Movatterモバイル変換

[0]ホーム
URL:

MXPA03008762A - Nicotine-containing oral dosage form. - Google Patents

Nicotine-containing oral dosage form.

Info

Publication number
MXPA03008762A
MXPA03008762AMXPA03008762AMXPA03008762AMXPA03008762AMX PA03008762 AMXPA03008762 AMX PA03008762AMX PA03008762 AMXPA03008762 AMX PA03008762AMX PA03008762 AMXPA03008762 AMX PA03008762AMX PA03008762 AMXPA03008762 AMX PA03008762A
Authority
MX
Mexico
Prior art keywords
oral dosage
nicotine
dosage form
containing oral
directed
Prior art date
Application number
MXPA03008762A
Other languages
Spanish (es)
Inventor
John Liu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham CorpfiledCriticalSmithkline Beecham Corp
Publication of MXPA03008762ApublicationCriticalpatent/MXPA03008762A/en

Links

Classifications

Landscapes

Abstract

The present invention is directed to glassy matrix solid oral dosage forms useful for transmucosal oral administration of a nicotine active.
MXPA03008762A2001-03-262002-03-22Nicotine-containing oral dosage form.MXPA03008762A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US27860601P2001-03-262001-03-26
PCT/US2002/008914WO2002076211A1 (en)2001-03-262002-03-22Nicotine-containing oral dosage form

Publications (1)

Publication NumberPublication Date
MXPA03008762Atrue MXPA03008762A (en)2004-02-18

Family

ID=23065632

Family Applications (1)

Application NumberTitlePriority DateFiling Date
MXPA03008762AMXPA03008762A (en)2001-03-262002-03-22Nicotine-containing oral dosage form.

Country Status (11)

CountryLink
EP (1)EP1372392A4 (en)
JP (1)JP2004525928A (en)
CN (2)CN1553771A (en)
AR (1)AR033444A1 (en)
AU (1)AU2002252470B2 (en)
BR (1)BR0208382A (en)
CA (1)CA2440713A1 (en)
MX (1)MXPA03008762A (en)
NZ (1)NZ528167A (en)
PL (1)PL364621A1 (en)
WO (1)WO2002076211A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040253307A1 (en)*2003-02-042004-12-16Brian HagueSugar-free oral transmucosal solid dosage forms and uses thereof
IL155666A (en)2003-04-292013-12-31Neurim Pharma 1991Composition for treating insomnia
US9119846B2 (en)2003-04-292015-09-01Neurim Pharmaceuticals (1991) Ltd.Method and composition for enhancing cognition in alzheimer's patients
PT2446881E (en)*2003-07-242014-06-11Glaxosmithkline LlcOrally dissolving films
GB0320854D0 (en)2003-09-052003-10-08Arrow No 7 LtdBuccal drug delivery
US8627828B2 (en)2003-11-072014-01-14U.S. Smokeless Tobacco Company LlcTobacco compositions
WO2005046363A2 (en)2003-11-072005-05-26U.S. Smokeless Tobacco CompanyTobacco compositions
EP1786272B1 (en)*2004-08-112014-11-05Intercontinental Great Brands LLCWarming compositions and delivery systems therefor
US8252321B2 (en)2004-09-132012-08-28Chrono Therapeutics, Inc.Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7780981B2 (en)2004-09-132010-08-24Chrono Therapeutics, Inc.Biosynchronous transdermal drug delivery
BRPI0719428A2 (en)*2006-12-012014-02-25Cima Labs Inc SOLID ORAL TRANSMUCOSAL DOSAGE FORM, METHOD FOR TREATING NICOTINE DEPENDENCE IN A RECEIVER WISHING SUCH TREATMENT, ORAL TRANSMUCOSAL NICOTINE DISTRIBUTION, AND NICOTINE REPLACEMENT METHOD.
GB2468424B (en)*2007-04-022011-11-09Parkinson S InstMethods and compositions for reduction of side effects of therapeutic treatments
GB2448224B (en)*2007-04-022010-09-01Parkinson S InstSolid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
DE102008012015A1 (en)*2008-03-012009-09-10Südzucker AG Mannheim/Ochsenfurt Improved isomalt-containing compresses and processes for their preparation
PH12012501487A1 (en)*2010-02-182016-07-27Jatin Vasant ThakkarNicotine-containing soft gelatin pastilles
US20110274628A1 (en)*2010-05-072011-11-10Borschke August JNicotine-containing pharmaceutical compositions
UA112974C2 (en)2010-09-162016-11-25Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид NICOTINE COMPOSITION (OPTIONS)
EP2729148A4 (en)2011-07-062015-04-22Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
US9629392B2 (en)2011-09-222017-04-25R.J. Reynolds Tobacco CompanyTranslucent smokeless tobacco product
US9084439B2 (en)2011-09-222015-07-21R.J. Reynolds Tobacco CompanyTranslucent smokeless tobacco product
US20130078307A1 (en)2011-09-222013-03-28Niconovum Usa, Inc.Nicotine-containing pharmaceutical composition
US9474303B2 (en)2011-09-222016-10-25R.J. Reynolds Tobacco CompanyTranslucent smokeless tobacco product
US9907748B2 (en)2011-10-212018-03-06Niconovum Usa, Inc.Excipients for nicotine-containing therapeutic compositions
US9044035B2 (en)2012-04-172015-06-02R.J. Reynolds Tobacco CompanyRemelted ingestible products
TW201507726A (en)*2013-05-102015-03-01Glaxosmithkline LlcNicotine lozenge formulation
CN104132895B (en)*2014-07-082017-08-25国家烟草质量监督检验中心The buffer system of total alkaloid tobacco and tobacco product is determined suitable for continuous flow method
WO2016123406A1 (en)2015-01-282016-08-04Chrono Therapeutics Inc.Drug delivery methods and systems
EP3267875A4 (en)2015-03-122018-12-05Chrono Therapeutics Inc.Craving input and support system
WO2018129304A1 (en)2017-01-062018-07-12Chrono Therapeutics Inc.Transdermal drug delivery devices and methods
SE541358C2 (en)*2017-05-302019-08-13Enorama Pharma AbNicotine-containing chewing gum compositions
CA3101966A1 (en)2018-05-292019-12-05Morningside Venture Investments LimitedDrug delivery methods and systems
JP2022507660A (en)2018-11-162022-01-18モーニングサイド ベンチャー インベストメンツ リミテッド Temperature-controlled transdermal drug delivery system
ES3034287T3 (en)*2019-06-072025-08-14Philip Morris Products SaNicotine pouch product
EP4090314A1 (en)*2020-01-152022-11-23McNeil ABLozenge
USD1081739S1 (en)2021-04-062025-07-01Altria Client Services LlcDie for gum forming
US20220313678A1 (en)*2021-04-062022-10-06Altria Client Services LlcSpray dried nicotine for inclusion in oral products
US12295412B2 (en)2022-01-282025-05-13Altria Client Services LlcOral pouch product

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB9310412D0 (en)*1993-05-201993-07-07Danbiosyst UkNasal nicotine system
US5549906A (en)*1993-07-261996-08-27Pharmacia AbNicotine lozenge and therapeutic method for smoking cessation
US5362496A (en)*1993-08-041994-11-08Pharmetrix CorporationMethod and therapeutic system for smoking cessation
DE19536394A1 (en)*1995-09-291997-04-03Basf Ag Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt
DE19639342C2 (en)*1996-09-251998-07-16Suedzucker Ag Chewing gum containing a sweetener
US6322806B1 (en)*1999-04-062001-11-27Wm. Wrigley Jr. CompanyOver-coated chewing gum formulations including tableted center

Also Published As

Publication numberPublication date
CN1553771A (en)2004-12-08
BR0208382A (en)2004-06-15
AR033444A1 (en)2003-12-17
CA2440713A1 (en)2002-10-03
EP1372392A1 (en)2004-01-02
JP2004525928A (en)2004-08-26
CN101301275A (en)2008-11-12
WO2002076211A1 (en)2002-10-03
EP1372392A4 (en)2004-06-23
NZ528167A (en)2005-04-29
PL364621A1 (en)2004-12-13
AU2002252470B2 (en)2008-05-22

Similar Documents

PublicationPublication DateTitle
MXPA03008762A (en)Nicotine-containing oral dosage form.
MXPA05002942A (en)Modified release oral dosage form.
UA84266C2 (en)Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyroolidon as excipient, processes for the preparation and use thereof
PL370292A1 (en)Formulations for oral administration of active compounds
PL356358A1 (en)Solid dosage form of someticone for oral administration
MXPA04004173A (en)Oral controlled release forms useful for reducing or preventing nicotine cravings.
HUP0302319A3 (en)Pharmaceutical composition for oral administration of active ingredient
NZ548215A (en)Effervescent oral opiate dosage form
MX2007015480A (en)Solid dosage formulations of narcotic drugs having improved buccal adsorption.
MY144659A (en)2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
TW200510375A (en)New compounds
TW200505498A (en)Sugar-free oral transmucosal solid dosage forms and uses thereof
NZ516347A (en)Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MXPA02002249A (en)Palatable pharmaceutical compositions for companion animals.
NO20011721D0 (en) N-aralkylaminotetralins as ligands for neuropeptide Y Y5 receptor
MXPA03006476A (en)Pharmaceutical dosage forms of epothilones for oral administration.
NZ527867A (en)Oral pharmaceutical composition of cefpodoxime proxetil
TWI264311B (en)Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
SE0100569D0 (en) New compounds
SE0103211D0 (en) New formulations and use thereof
AU2002214389A1 (en)Pharmaceutical composition containing honey for the treatment of wounds
SE0102440D0 (en) New compound
RS50593B (en)Containing lozenges used against inflammatory oral and pharyngeal diseases
SI1596841T1 (en)Therapeutic system comprising amoxicillin and clavulanic acid
PL359727A1 (en)Crystalline pharmaceutical

Legal Events

DateCodeTitleDescription
FGGrant or registration
[8]ページ先頭
©2009-2025 Movatter.jp